TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapyEva Nievergall, Deborah L. White, Mark Biondo et al.|Leukemia|2016Cited by 50
Destabilisation of dimeric 14-3-3 proteins as a novel approach to anti-cancer therapeuticsJoanna M. Woodcock, Angel F. López|Oncotarget|2015Cited by 38
GM‐CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid‐derived suppressor cells <i>in vitro</i>Tessa Gargett, Michael P. Brown, Susan N. Christo et al.|Clinical & Translational Immunology|2016Cited by 36
Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in LeukemiaWinnie L. Kan, Angel F. López|Cancer Discovery|2023Cited by 11